- Trials with a EudraCT protocol (421)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
421 result(s) found for: Ventilation rate.
Displaying page 5 of 22.
| EudraCT Number: 2020-001517-21 | Sponsor Protocol Number: I4V-MC-KHAA | Start Date*: 2020-06-30 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection | |||||||||||||
| Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001086-32 | Sponsor Protocol Number: 19-001_AMG | Start Date*: 2020-01-02 |
| Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | ||
| Full Title: ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study | ||
| Medical condition: Patients undergoing high-risk open-heart surgery with the use of cardiopulmonary bypass (CPB) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-001027-33 | Sponsor Protocol Number: PAFIBAR1.0 | Start Date*: 2023-06-07 | |||||||||||
| Sponsor Name:FIMABIS | |||||||||||||
| Full Title: Evaluation of the effect of Opioid-Free Anesthesia on oxygenation in bariatric surgery | |||||||||||||
| Medical condition: Bariatric surgery | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001571-32 | Sponsor Protocol Number: APHP200406 | Start Date*: 2020-04-15 |
| Sponsor Name:Assistance Publique Hôpitaux de Paris | ||
| Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001686-36 | Sponsor Protocol Number: 2020-21 | Start Date*: 2020-04-23 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | |||||||||||||
| Full Title: A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia | |||||||||||||
| Medical condition: Coronavirus infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000269-34 | Sponsor Protocol Number: GC2010 | Start Date*: 2021-03-20 | ||||||||||||||||||||||||||
| Sponsor Name:Grifols Therapeutics LLC | ||||||||||||||||||||||||||||
| Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory... | ||||||||||||||||||||||||||||
| Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-005059-35 | Sponsor Protocol Number: TMP-2204-2021-47 | Start Date*: 2022-01-25 | ||||||||||||||||
| Sponsor Name:F4-Pharma GmbH i.G. | ||||||||||||||||||
| Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0) | ||||||||||||||||||
| Medical condition: Acute Respiratory Distress Syndrome (ARDS) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-000620-18 | Sponsor Protocol Number: RC20_0082 | Start Date*: 2021-02-19 | ||||||||||||||||
| Sponsor Name:Nantes University Hospital | ||||||||||||||||||
| Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the... | ||||||||||||||||||
| Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-002249-40 | Sponsor Protocol Number: GNS561CLIQ0291 | Start Date*: 2020-06-30 | |||||||||||
| Sponsor Name:Genoscience Pharma | |||||||||||||
| Full Title: Cure COVID: A prospective, controlled, randomized study to compare the efficacy of GNS561 versus standard of care in patients with SARS-CoV-2 (COVID-19) infection. | |||||||||||||
| Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004646-33 | Sponsor Protocol Number: DORINOS3008 | Start Date*: 2008-07-08 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects with Ventilato... | |||||||||||||
| Medical condition: Ventilator-Associated Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) BE (Completed) PT (Prematurely Ended) DE (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004422-29 | Sponsor Protocol Number: ISIS396443-CS3B | Start Date*: 2014-11-13 | |||||||||||
| Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Mus... | |||||||||||||
| Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) GB (Completed) ES (Completed) SE (Completed) DE (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001673-75 | Sponsor Protocol Number: ABX464-401 | Start Date*: 2020-05-06 |
| Sponsor Name:ABIVAX | ||
| Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu... | ||
| Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002497-27 | Sponsor Protocol Number: KFJ-2020-01_IMUNOR | Start Date*: 2020-10-27 |
| Sponsor Name:Thomayerova nemocnice | ||
| Full Title: A randomized, open-label, phase IV monocentric study evaluating the clinical effect of oral immunomodulatory therapy with IMUNOR® in patients with moderate COVID-19 disease | ||
| Medical condition: Patients with COVID -19 disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004682-39 | Sponsor Protocol Number: KFJ-2020-02_NORMOSANG | Start Date*: 2020-11-16 |
| Sponsor Name:Thomayerova nemocnice | ||
| Full Title: Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease | ||
| Medical condition: Patients with COVID -19 disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001449-38 | Sponsor Protocol Number: CW002 | Start Date*: 2020-04-29 | |||||||||||
| Sponsor Name:Chelsea and Westminster Hospital NHS Foundation Trust | |||||||||||||
| Full Title: A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe | |||||||||||||
| Medical condition: COVID-19 Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000399-12 | Sponsor Protocol Number: GPHIP_0202 | Start Date*: 2021-04-16 | |||||||||||
| Sponsor Name:Grand Medical Pty Ltd | |||||||||||||
| Full Title: A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia | |||||||||||||
| Medical condition: severe pneumonia due to COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001244-26 | Sponsor Protocol Number: COV-2-SOLNATIDE-20 | Start Date*: 2020-04-11 | ||||||||||||||||
| Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria | ||||||||||||||||||
| Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial. | ||||||||||||||||||
| Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-001306-35 | Sponsor Protocol Number: APHP200394 | Start Date*: 2020-04-05 |
| Sponsor Name:DRCI APHP | ||
| Full Title: Protective role of inhaled steroids for COVID-19 infection | ||
| Medical condition: COVID-19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001110-38 | Sponsor Protocol Number: TOCIVID-19 | Start Date*: 2020-03-18 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE" | |||||||||||||
| Full Title: Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia | |||||||||||||
| Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001541-39 | Sponsor Protocol Number: BEVACOR | Start Date*: 2020-04-24 | ||||||||||||||||
| Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
| Full Title: Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
| Medical condition: Acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.